Cipla Share Price

Sector: Pharmaceuticals | ISIN: INE059A01026

₹ 1,488.65 (0.65%)

2 Jul, 2024, 12:00:00 AM

Trade

Expiry Date:

CIPLA - 25-07-2024

CALLS						PUTS
Total OI	Chg in Ol	Chg % Ol	LTP	Chg %	Strike Price	Chg %	LTP	Chg % OI	Chg in Ol	Total OI
3250	0	0.00	181	0.00	1,300.00	-18.18	0.9	32.69	11050	44850
-	-	-	-	0.00	1,320.00	-52.73	1.3	-7.69	-650	7800
-	-	-	-	0.00	1,340.00	-17.65	1.4	74.0	24050	56550
650	0	0.00	135.65	0.00	1,360.00	-17.02	1.95	-12.31	-10400	74100
0	0	0.00	112.35	0.00	1,380.00	-21.13	2.8	0.0	0	53950
42250	18200	75.68	101.1	75.68	1,400.00	-21.43	4.4	1.54	3900	257400
4550	1950	75.00	82.55	75.00	1,420.00	-19.65	6.95	12.5	9750	87750
13650	5200	61.54	63.9	61.54	1,440.00	-19.70	10.6	27.7	38350	176800
44200	18850	74.36	52.05	74.36	1,460.00	-18.27	16.1	2.74	6500	243750
299000	-33150	-9.98	39.95	-9.98	1,480.00	-15.33	23.75	27.34	74100	345150

Cipla Ltd Corporate Actions

05 Apr , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

03 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

03 Jan , 2024

12:00 AM

Results

View Details

06 Nov , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

04 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

04 Oct , 2023

12:00 AM

Results

View Details

11 Jul , 2023

12:00 AM

AGM

Announcement date: 11 Jul , 2023

View Details

04 Jul , 2023

12:00 AM

Results

View Details

04 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

11 May , 2023

12:00 AM

Dividend

Dividend amount: 8.5
Announcement date: 11 May , 2023

View Details

No Record Found

Cipla Ltd News and Update

Cipla to invest Euro 3 million Ethris

Cipla stated in an exchange statement that this extra investment, made through a convertible loan, will accelerate the company's engagement in the mRNA space.

Cipla gets USFDA approval for its generic acromegaly drug

Lanreotide Injection is indicated for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumors.

23 May, 2024 |
12:27 PM

Cipla to invest Rs 26 crore in Achira Labs' preference shares

Cipla primarily develops drugs to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, etc.

16 May, 2024 |
1:02 PM

Cipla promoters may sell up to 2.53% of their stake today

On May 10, Cipla announced a 10% increase in revenue to ₹6,163 Crore and a 79% increase in fourth-quarter profit to ₹939 Crore.

15 May, 2024 |
9:48 AM

Cipla Ltd FINANCIALS

Y/e 31 Mar( In .Cr)	Mar-2022	Mar-2021	Mar-2018	Mar-2017
Revenue	21763.34	19159.59	15155.71	14394.29
yoy growth (%)	13.59	26.42	5.29	5.88
Raw materials	(8,495.60)	(7,351.89)	(5,438.42)	(5,317.12)
As % of sales	39.04	38.37	35.88	36.94
Employee costs	(3,529.91)	(3,251.83)	(2,690.10)	(2,633.82)
As % of sales	16.22	16.97	17.75	18.30
Other costs	(5,185.05)	(4,303.44)	(4,200.81)	(3,967.56)
As % of sales	23.82	22.46	27.72	27.56
Operating profit	4552.78	4252.43	2826.38	2475.79
OPM	20.92	22.20	18.65	17.20
Depreciation	(1,051.95)	(1,067.66)	(1,322.82)	(1,322.93)
Interest expense	(106.35)	(160.70)	(114.23)	(159.38)
Other income	280.91	265.99	357.65	228.69
Profit before tax	3675.39	3290.06	1746.98	1222.17
Taxes	(933.80)	(888.76)	(250.11)	(179.76)
Tax rate	(25.41)	(27.01)	(14.32)	(14.71)
Minorities and other	(42.72)	3.57	(8.82)	(36.02)
Adj. profit	2698.87	2404.87	1488.05	1006.39
Exceptional items	(182.12)	--	(77.52)	--
Net profit	2516.75	2404.87	1410.53	1006.39
yoy growth (%)	4.65	70.49	40.16	(26)
NPM	11.56	12.55	9.31	6.99

Y/e 31 Mar ( In .Cr)	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Equity capital	161.43	161.36	161.29	161.25
Preference capital	--	--	--	--
Reserves	23246.35	20680.33	18165.24	15601.75
Net worth	23407.78	20841.69	18326.53	15,763
Minority interest	305.76	275.69	259.06	294.28
Debt	803.12	1055.78	2014.41	2816.43
Deferred tax liabilities (net)	1461.12	1675.39	296.61	365.21
Total liabilities	25977.78	23848.55	20896.61	19238.92
Fixed assets	10253.78	10449.51	10484.41	10507.42
Intangible assets	--	--	--	--
Investments	3662.38	2550.60	2710.05	1471.02
Deferred tax asset (net)	1754.38	1880.26	314.69	239.77
Net working capital	8742.62	7039.70	5986.23	6016.80
Inventories	5156.43	5350.24	4669.18	4377.60
Inventory Days	--	89.73	88.95	--
Sundry debtors	4,057	3424.44	3445.68	3891.31
Debtor days	--	57.43	65.64	--
Other current assets	4312.53	2949.02	2126.65	2171.53
Sundry creditors	(2,568.26)	(2,591.02)	(2,122.42)	(2,343.15)
Creditor days	--	43.45	40.43	--
Other current liabilities	(2,215.08)	(2,092.98)	(2,132.86)	(2,080.49)
Cash	1564.62	1928.48	1401.23	1003.91
Total assets	25977.78	23848.55	20896.61	19238.92

Y/e 31 Mar ( In .Cr)	Mar-2022	Mar-2021	Mar-2018	Mar-2017
Profit before tax	3675.39	3290.06	1746.98	1222.17
Depreciation	(1,051.95)	(1,067.66)	(1,322.82)	(1,322.93)
Tax paid	(933.80)	(888.76)	(250.11)	(179.76)
Working capital 27,893	5008.94	4216.75	2959.49	1284.78
Other operating items	--	--	--	--
Operating cashflow	6698.58	5550.39	3133.54	1004.26
Capital expenditure	12727.57	11160.20	7643.60	2678.31
Free cash flow	19426.15	16710.59	10777.14	3682.57
Equity raised	24669.91	23239.43	21757.72	21427.36
Investments	1959.83	1440.94	(1,273.60)	264.44
Debt financing/disposal	1591.77	2023.58	5046.14	4658.57
Dividends paid	--	--	241.54	160.90
Net in cash	47647.66	43414.54	36548.93	30193.84

Y/e 31 Mar	Mar-2022	Mar-2021	Mar-2018	Mar-2017
Growth matrix (%)
Revenue growth	13.59	26.418	5.29	5.88
Op profit growth	7.063	50.455	14.161	-0.156
EBIT growth	9.592	85.404	34.719	-28.553
Net profit growth	4.652	70.494	40.157	-26
Profitability ratios (%)
OPM	20.919	22.195	18.649	17.2
EBIT margin	17.377	18.011	12.281	9.598
Net profit margin	11.564	12.552	9.307	6.992
RoCE	16.903	17.22	10.051	7.587
RoNW	3.213	3.693	2.634	2.091
RoA	2.812	3	1.904	1.382
Per share ratios (₹)
EPS	31.72	29.78	17.63	12.96
Dividend per share	5	5	3	2
Cash EPS	18.155	16.581	1.089	-3.935
Book value per share	16.903	17.22	10.051	7.587
Valuation ratios
P/E	32.109	27.376	30.814	45.702
P/CEPS	56.099	49.167	498.667	-150.537
P/B	3.943	3.588	3.074	3.799
EV/EBIDTA	16.82	14.687	14.721	18.909
Payout (%)
Dividend payout	0	0	17.124	15.988
Tax payout	-25.407	-27.013	-14.317	-14.708
Liquidity ratios
Debtor days	57.611	62.373	68.222	62.37
Inventory days	84.019	83.002	90.674	92.469
Creditor days	-49.981	-52.917	-58.348	-49.918
Leverage ratios
Interest coverage	-35.559	-21.473	-16.294	-8.668
Net debt / equity	-0.042	0.033	0.22	0.278
Net debt / op. profit	-0.192	0.144	1.108	1.409
Cost breakup (₹)
Material costs	-39.036	-38.372	-35.884	-36.939
Employee costs	-16.22	-16.972	-17.75	-18.298
Other costs	-23.825	-22.461	-27.718	-27.563

Select Period:

Particulars ( Rupees In Crores.)	--	--	--	--
Gross Sales	--	--	--	--
Excise Duty	--	--	--	--
Net Sales	--	--	--	--
Other Operating Income	--	--	--	--
Other Income	--	--	--	--
Total Income	--	--	--	--
Total Expenditure **	--	--	--	--
PBIDT	--	--	--	--
Interest	--	--	--	--
PBDT	--	--	--	--
Depreciation	--	--	--	--
Minority Interest Before NP	--	--	--	--
Tax	--	--	--	--
Deferred Tax	--	--	--	--
Reported Profit After Tax	--	--	--	--
Minority Interest After NP	--	--	--	--
Net Profit after Minority Interest	--	--	--	--
Extra-ordinary Items	--	--	--	--
Adjusted Profit After Extra-ordinary item	--	--	--	--
EPS (Unit Curr.)	--	--	--	--
Book Value (Unit Curr.)	--	--	--	--
Dividend (%)	--	--	--	--
Equity	--	--	--	--
Public Shareholding (Number)	--	--	--	--
Public Shareholding (%)	--	--	--	--
Pledged/Encumbered - No. of Shares	--	--	--	--
Pledged/Encumbered - % in Total Promoters Holding	--	--	--	--
Pledged/Encumbered - % in Total Equity	--	--	--	--
Non Encumbered - No. of Shares	--	--	--	--
Non Encumbered - % in Total Promoters Holding	--	--	--	--
Non Encumbered - % in Total Equity	--	--	--	--
PBIDTM(%)	--	--	--	--
PBDTM(%)	--	--	--	--
PATM(%)	--	--	--	--

No Record Found

Particulars ( Rupees In Crores.)	--	--	--	--
Gross Sales	--	--	--	--
Excise Duty	--	--	--	--
Net Sales	--	--	--	--
Other Operating Income	--	--	--	--
Other Income	--	--	--	--
Total Income	--	--	--	--
Total Expenditure **	--	--	--	--
PBIDT	--	--	--	--
Interest	--	--	--	--
PBDT	--	--	--	--
Depreciation	--	--	--	--
Minority Interest Before NP	--	--	--	--
Tax	--	--	--	--
Deferred Tax	--	--	--	--
Reported Profit After Tax	--	--	--	--
Minority Interest After NP	--	--	--	--
Net Profit after Minority Interest	--	--	--	--
Extra-ordinary Items	--	--	--	--
Adjusted Profit After Extra-ordinary item	--	--	--	--
EPS (Unit Curr.)	--	--	--	--
Book Value (Unit Curr.)	--	--	--	--
Dividend (%)	--	--	--	--
Equity	--	--	--	--
Public Shareholding (Number)	--	--	--	--
Public Shareholding (%)	--	--	--	--
Pledged/Encumbered - No. of Shares	--	--	--	--
Pledged/Encumbered - % in Total Promoters Holding	--	--	--	--
Pledged/Encumbered - % in Total Equity	--	--	--	--
Non Encumbered - No. of Shares	--	--	--	--
Non Encumbered - % in Total Promoters Holding	--	--	--	--
Non Encumbered - % in Total Equity	--	--	--	--
PBIDTM(%)	--	--	--	--
PBDTM(%)	--	--	--	--
PATM(%)	--	--	--	--

No Record Found

Cipla Ltd PEER COMPARISON

Company Name	LTP (₹)	P/E (%)	Mkt.Cap (₹Cr.)	NP Qtr (₹Cr.)	Div.Yield (%)	Sales Qtr (₹.Cr)	Book Value (₹)
Sun Pharmaceuticals Industries Ltd	1,524.10	120.29	3,65,682.64	867.60	0.89	5,536.99	98.75
Divis Laboratories Ltd	4,569.75	76.97	1,21,312.50	531.00	0.66	2,259.00	507.94
Cipla Ltd	1,488.45	32.36	1,20,195.02	1,038.40	0.57	3,444.92	346.42
Zydus Lifesciences Ltd	1,074.45	31.35	1,08,114.81	1,405.20	0.28	3,172.60	156.19
Dr Reddys Laboratories Ltd	6,371.65	24.48	1,06,298.05	1,034.80	0.63	5,081.80	1,453.03

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Cipla Ltd

Y K Hamied
Chairman (Non-Executive)

M K Hamied
Vice Chairman

S Radhakrishnan
Non-Exec & Non-Independent Dir

Ashok Sinha
Non-Exec. & Independent Dir.

Peter Mugyenyi
Non-Exec. & Independent Dir.

Adil Zainulbhai
Non-Exec. & Independent Dir.

Punita Lal
Non-Exec. & Independent Dir.

Samina Hamied
Executive Vice Chairperson

Umang Vohra
Managing Director & Global CEO

Rajendra Chopra
Company Sec. & Compli. Officer

Robert A Stewart
Independent Director

P R Ramesh
Independent Director

Mandar Purushottam Vaidya
Independent Director

Summary

Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). Ciplas product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets. Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Ltd was incorporated in the year 1935 with the name Chemical, Industrial & Pharmaceutical Laboratories Ltd. Khwaja Abdul Hamied, the founder of Cipla gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorized capital of Rs 6 lakh. From its first manufacturing unit at Bombay Central in 1936, Cipla now has over 40 state-of-the art manufacturing facilities across the globe including India, USA, China and South Africa.In the year 1941, as the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities for the war effort. In the year 1952, the company... Read More

Reports by Cipla Ltd
Annual ReportAuditors Report
Management DiscussionDirectors Report

Reports by Cipla Ltd
Investor PresentationConference Call TranscriptConference Call Audio

ATTENTION INVESTORS

Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

Risk Disclosure on Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to Rs. 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This certificate demonstrates that IIFL as an organization has defined and put in place best-practice information security processes.

Cipla Share Price

Expiry Date:

Expiry Date:

Cipla Ltd KEY RATIOS

Cipla Ltd KEY RATIOS

Cipla Ltd Corporate Actions

Cipla Ltd Corporate Actions

Cipla Ltd News and Update

Cipla Ltd News and Update

Cipla to invest Euro 3 million Ethris

Cipla gets USFDA approval for its generic acromegaly drug

Cipla to invest Rs 26 crore in Achira Labs' preference shares

Cipla promoters may sell up to 2.53% of their stake today

Knowledge Center

Cipla Ltd SHAREHOLDING SNAPSHOT 03 July , 2024 | 06:49 AM

Cipla Ltd SHAREHOLDING SNAPSHOT 03 July , 2024 | 06:49 AM

Cipla Ltd FINANCIALS

Cipla Ltd FINANCIALS

Select Period:

QuickLinks for Cipla Ltd.

Cipla Information

Cipla Financials

Cipla Results

Cipla News

Cipla Ltd PEER COMPARISON

Cipla Ltd PEER COMPARISON

MORE ABOUT Cipla Ltd

MORE ABOUT Cipla Ltd

Summary

Company FAQ

Cipla Share Price

Equities

Futures

Option

Expiry Date:

Expiry Date:

Cipla Ltd KEY RATIOS

Cipla Ltd KEY RATIOS

Cipla Ltd Corporate Actions

Cipla Ltd Corporate Actions

Cipla Ltd News and Update

Cipla Ltd News and Update

News

LiAS Events

Cipla to invest Euro 3 million Ethris

Cipla gets USFDA approval for its generic acromegaly drug

Cipla to invest Rs 26 crore in Achira Labs' preference shares

Cipla promoters may sell up to 2.53% of their stake today

Knowledge Center

Cipla Ltd SHAREHOLDING SNAPSHOT 03 July , 2024 | 06:49 AM

Cipla Ltd SHAREHOLDING SNAPSHOT 03 July , 2024 | 06:49 AM

Cipla Ltd FINANCIALS

Cipla Ltd FINANCIALS

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Results

Select Period:

QuickLinks for Cipla Ltd.

Cipla Information

Cipla Financials

Cipla Results

Cipla News

Cipla Ltd PEER COMPARISON

Cipla Ltd PEER COMPARISON

MORE ABOUT Cipla Ltd

MORE ABOUT Cipla Ltd

Management

Register Office

Registrar Office

Summary

Company FAQ